Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review summarizes the adverse effects associated with 5α‐reductase inhibitors, noting slightly increased rates of decreased libido, erectile and ejaculatory dysfunction, gynecomastia, depression, and anxiety, with further studies needed to explore symptom prevalence and persistence.

This study found that for men with moderate-to-severe LUTS/BPH, 6 months of treatment with tamsulosin plus the hexanic extract of S. repens was as effective as tamsulosin plus a 5-alpha-reductase inhibitor but had better tolerability.

This review discusses previously reported cases of drug-associated hidradenitis suppurativa linked to various immunomodulating medications but reports no new clinical results.

This review discusses the neuroprotective properties of Nigella sativa and its nanoformulations for treating neurodegenerative disorders, without presenting new clinical results.

This study explored the solubility and crystal structure of GI197111X, a 5-alpha reductase inhibitor for androgenetic alopecia, finding its solubility in Capmul MCM suitable for a soft gel dosage form.

This study analyzed safety data for semaglutide, liraglutide, and tirzepatide from the EudraVigilance database, identifying potential safety signals not listed in current SmPCs, such as optic ischemic neuropathy and pancreatitis, underscoring the importance of ongoing pharmacovigilance.

Finasteride's sexual side effects not caused by androgen deficiency or SRD5A inhibition.

This meta-analysis reported that the use of 5α-reductase inhibitors significantly increased the risk of postfinasteride syndrome-like adverse effects in men treated for benign prostatic hyperplasia or androgenetic alopecia.

In this study, researchers reported significant improvement in sexual function and related symptoms for four patients using off-label flibanserin, suggesting potential broader applications beyond premenopausal women with hypoactive sexual desire disorder.

This study reports that structural and biochemical analysis of steroid 5α-reductases clarifies how they mediate steroid reduction with NADPH, potentially aiding in designing targeted therapies.

Results are not reported in this commentary, but it discusses the influence of different control group choices—an active-comparator versus non-drug users—on measuring depression risk in studies of 5-alpha reductase inhibitors.

This study found that low-dose finasteride treatment in men with premature androgenetic alopecia decreased levels of 5α-reduced steroids, which may be linked to increased depression symptoms.

This study found that in rats, finasteride significantly reduced allopregnanolone in the cortex and increased both the rise and duration of dopamine levels in the prefrontal cortex in response to stress and anxiogenic stimuli.

This study found that finasteride significantly reduced dihydrotestosterone levels but did not provide clear evidence of impaired libido or erectile function compared to placebo in men.

This retrospective pharmacovigilance study identified 34 drugs, including finasteride and dutasteride, that may be associated with sexual dysfunction, with a higher risk observed in males aged 31-45.

In this study, finasteride was found to potentiate stress-induced disruption in sensory gating of rats by neutralizing the increase in allopregnanolone levels after acute stress.

This study found that repeated finasteride administration in male Wistar rats led to increased depression-like behavior, suggesting an animal model for investigating finasteride's neuropsychiatric effects is viable.

In this study, patients who were informed about finasteride's sexual side effects reported them significantly more often than those who were not, highlighting a potential nocebo effect.

This study found that patients with post-finasteride syndrome exhibited major depressive disorder, severe erectile dysfunction, and neuropathy, alongside altered neuroactive steroid levels in cerebrospinal fluid.

This study in neonatal rats found that inhibiting neurosteroid synthesis with finasteride unexpectedly reduced the severity and duration of neonatal seizures following birth asphyxia, maintained cognitive functions, but increased anxiety-like behaviors, highlighting a complex role of neurosteroids in hypoxic-ischemic encephalopathy outcomes.

In these two clinical trials, DS-2325a, a KLK5 inhibitor, was found to be generally safe and well tolerated in healthy volunteers, with mild and non-serious adverse events, suggesting its potential for further development as a treatment for Netherton Syndrome.

This review analyzes existing literature on prognostic factors for renal cell carcinoma, highlighting the need for continuous updates of prognostic models to reflect advancement in molecular pathway knowledge and targeted therapies.

This article reviews studies on younger men using finasteride for hair loss, finding persistent sexual and nonsexual side effects like erectile dysfunction and depression, and reports lower neurosteroid levels in affected individuals.

This study suggests that weekly oral finasteride may be a promising alternative to isotretinoin for treating nodulocystic acne, showing substantial improvements with lower incidence of sexual dysfunction.

Finasteride, a hair loss drug, is linked to increased suicidal thoughts, particularly when used for hair loss.

This study found that subchronic finasteride treatment in male rats altered neuroactive steroid levels and steroid receptor expression in the brain, with some changes persisting after drug withdrawal.

5α-reductase inhibitors may increase the risk of depression and suicidal thoughts.